CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2022	Jan. 01, 2022
Cash Flows from Operating Activities:
Net income	$ 86,018	$ 33,634
Non-cash items:
Depreciation and amortization	69,453	72,934
Impairment of assets	94	5,144
Share-based compensation expense	18,525	19,262
Amortization of deferred financing costs	1,098	2,608
Provision (benefit ) for losses on inventory	483	(280)
Gain on closing of transaction	382	9,603
Contingent consideration	(504)	10,272
Other non-cash operating activities	1,046	8,397
Change in operating assets and liabilities:
Change in accounts receivable	(24,370)	(28,736)
Change in inventories	34,506	11,589
Change in prepaid income taxes	1,970	4,400
Change in other assets and other liabilities	(10,664)	(6,010)
Change in accounts payable and accrued expenses	16,174	(19,398)
Net cash provided by operating activities	193,447	104,213
Cash Flows from Investing Activities:
Capital expenditures	(98,272)	(61,394)
Acquisition	(2,850)	(2,500)
Proceeds from divestiture	850	10,642
Proceeds from sale of property, plant and equipment	7,695	1,419
Other investments	(33,205)	0
Net cash used in investing activities	(125,782)	(51,833)
Cash Flows from Financing Activities:
Term loan borrowings	280,000	0
Term loan redemption	(280,000)	0
Proceeds from revolving facility	50,000	0
Repayments of Long-term Lines of Credit	(50,000)	0
Repayment of term loan borrowings	(7,875)	(13,125)
Debt issuance costs	(1,118)	0
Share repurchases	(75,000)	0
Contingent consideration payments	(21,593)	0
Proceeds from employee stock purchase plan	4,378	4,210
Proceeds from exercise of stock options	2,479	1,923
Other	(32)	8
Net cash used in financing activities	(98,761)	(6,984)
Effect of exchange rates on cash and cash equivalents	(4,398)	(824)
Net Change in Cash and Cash Equivalents	(35,494)	44,572
Cash and Cash Equivalents at Beginning of Period	259,496	192,305
Cash and Cash Equivalents at End of Period	224,002	236,877
Supplemental Disclosures of Cash Flow Information:
Transfers from inventory to fixed assets for placement of Haemonetics equipment	$ 77,946	$ 25,385